Product Theater: Astellas - Learn About a Nonhormonal FDA-Approved Treatment for Moderate to Severe Vasomotor Symptoms Due to Menopause
Wednesday, December 9, 2026, – (America/New_York)
Product Theater
In this session, we will review an FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.
Click here to download the VEOZAHTM (fezolinetant) Prescribing Information
Click here to access the Post Program Survey
For further product information please click here
Speakers
-
DNP, APRN, BC, CSC, MSCP, FAAN, FAANP